Diagnostics · 2021 · 32 citations · 25 references
MedicineNuclear MedicineOncologyOncologic Nuclear MedicineRadiation DosimetryTherapeutic Nuclear MedicineIn Vivo DosimetryProstate CancerProstate Cancer ImagingProstate Cancer Radioligand TherapyRadiation TherapyTherapy Response AssessmentBiochemical Response AssessmentClinical Outcome MeasurementProstate-specific Antigen - Targeted TherapyProstate-specific Membrane Antigen PetProstate-specific Membrane Antigen RadioligandsTargeted Radioligand TherapyTumor DosimetryWhole-body Dosimetry
Background: Dosimetry can tailor prostate-specific membrane-antigen-targeted radioligand therapy (PSMA-RLT) for metastatic castration-resistant prostate cancer (mCRPC). However, whole-body tumor dosimetry is challenging in patients with a high tumor burden. We evaluate a simplified index-lesion-based single-photon emission computed tomography (SPECT) dosimetry method in correlation with clinical outcome. Methods: 30 mCRPC patients were included (median 71 years). The dosimetry was performed for the first cycle using quantitative 177Lu-SPECT. The response was evaluated using RECIST 1.1 and PERCIST criteria, as well as changes in PSMA-positive tumor volume (PSMA-TV) in post-therapy PSMA-PET and biochemical response according to PSA changes after two RLT cycles. Results: Mean tumor doses as well as index-lesion doses were significantly higher in PERCIST responders compared to non-responders (10.2 ± 12.0 Gy/GBq vs. 4.0 ± 2.9 Gy/GBq, p = 0.03 and 13.7 ± 14.2 Gy/GBq vs. 5.9 ± 4.4 Gy/GBq, p = 0.04, respectively). No significant differences in mean tumor and index lesion doses were observed between responders and non-responders according to RECIST 1.1, PSMA-TV, and biochemical response criteria. Conclusion: Compared to mean tumor doses on a patient level, single index-lesion-based SPECT dosimetry correlates equally well with the response to PSMA-RLT according to PERCIST criteria and may represent a fast and feasible dosimetry approach for clinical routine.
25
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Michael S. Hofman, John Violet, Rodney J. Hicks et al. · The Lancet Oncology · 2018 · 1.1K citations
Medicine, Nuclear Medicine, Oncology +14
Frederik L. Giesel, Boris Hadaschik, Jens Cardinale et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2016 · 602 citations · Full text
Richard P. Baum, Harshad Kulkarni, Christiane Schuchardt et al. · Journal of Nuclear Medicine · 2016 · 526 citations · Full text
Medicine, Nuclear Medicine, Oncology +17
John Violet, Price Jackson, Justin Ferdinandus et al. · Journal of Nuclear Medicine · 2018 · 486 citations · Full text
Medicine, Nuclear Medicine, Oncology +17